If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
222
results.
Updated on
05/06/2025 [06:55:00]
Absstract of: WO2024026487A1
The present disclosure provides lipid assemblies suitable for delivery of therapeutic agents to hematopoietic stem and progenitor cells (HSPCs), wherein the lipid assemblies comprise a phosphatidylserine phospholipid. The present disclosure also provides therapeutic and diagnostic uses related to the lipid assemblies.
Absstract of: WO2024030865A2
Disclosed are compositions, systems, and methods involving lipid nanoparticle primarily composed of phosphatidic acid (PA), monogalactosyldiacylglycerol (MGDG), and digalactosyldiacylglycerol (DGDG). In particular, the PA, MGDG, and DGDG are present in the nanoparticles in useful ratios, preferably falling in a ratio of 3 to 7, 1 to 3, and 2 to 4, respectively. Further, it is useful for the PA, MGDG, and DGDG to make up 90% or more of the total lipid in the nanoparticles. The disclosed lipid nanoparticles are useful as drug delivery systems for delivery of a drug, such as oral delivery, intravascular delivery, or intramuscular delivery. The disclosed lipid nanoparticles can be used in methods involving administration or delivery of the nanoparticles to a subject. In some forms, the subject can be a disease or condition, such as inflammatory bowel disease, ulcerative colitis, Crohn's disease, cancer, colon cancer, or a coronavirus infection.
Absstract of: WO2024023504A1
The present invention relates to compositions comprising an extracellular vesicle (EV). In particular, the extracellular vesicle (EV) comprises a single pass EV transmembrane protein fused to a moiety on the surface of the EV and/or a cargo molecule. The composition may be used to deliver the cargo molecule. Methods of manufacturing the composition are also provided.
Absstract of: AU2023313035A1
The invention concerns a novel and innovative composition for the treatment of neuropathic pain (NP). Specifically, the invention concerns HfO
Absstract of: AU2023313035A1
The invention concerns a novel and innovative composition for the treatment of neuropathic pain (NP). Specifically, the invention concerns HfO
Absstract of: WO2024023361A1
Nanoparticles suitable for delivery of a cargo to a chondrocyte, and targeting peptides comprising a chondrocyte targeting sequence, are provided. Further provided are uses of the nanoparticles and targeting peptides, for example, in treating a joint or cartilage disease or disorder.
Absstract of: CN119698325A
The present invention relates to microcapsules based on a polymeric shell and a lipophilic active core material with improved thermal stability.
Absstract of: WO2024026482A1
The present disclosure provides lipid assemblies suitable for delivery of therapeutic agents to hematopoietic stem and progenitor cells (HSPCs), wherein the lipid assemblies comprise a neutral polymer surface lipid. The present disclosure also provides therapeutic and diagnostic uses related to the lipid assemblies.
Absstract of: EP4563528A1
The present invention relates to a silica mesoporous nanoparticle comprising a covalently bound protein G' or protein A, the composition comprising said nanoparticle, the use thereof for capturing, purifying, eliminating and/or isolating immunoglobulins, preferably IgG, as well as a method for purifying an immunoglobulin, methods for pre-treating samples in order to subsequently diagnose allergies, infections and/or autoimmune diseases in a patient, and said diagnostic methods.
Absstract of: EP4563142A1
The present invention relates to lipid nanoparticles capable of delivering a target substance to hepatic stellate cells. The lipid nanoparticles are for delivering a target substance to hepatic stellate cells and comprise a pH-sensitive cationic lipid including a hydrophilic portion and two hydrophobic portions, wherein an acid dissociation constant pKa of a lipid membrane constituting the lipid nanoparticles is greater than or equal to 6.7 and less than 8.2.
Absstract of: WO2024026029A2
Disclosed are compositions and methods related to lipid nanoparticles (LNPs) comprising ionizable lipids. The LNPs can comprise nucleic acid sequences encoding therapeutic peptides for immunotherapy, for example, bispecific antibodies or antigen binding fragments thereof.
Absstract of: WO2024026444A1
Non-invasive, in situ forming depots for delivery of a therapeutic agents, containing heterodimerizing, synthetic leucine zippers for physical crosslinking mediated by competition-based dimerization. The heterodimerizing, synthetic leucine zippers form a self-assembling depot of the therapeutic agent at a target site in vivo. A library of such heterodimerizing, synthetic leucine zippers is provided, as well as methods of treating subjects using the same.
Absstract of: CN120078740A
本发明公开了一种基于铁蛋白纳米平台的毛细胞保护剂及其治疗听力损失的应用，属于生物医药领域，本发明的负载升麻素的铁蛋白纳米粒，包括作为载体的铁蛋白(Fn)和负载在铁蛋白中的升麻素(Ci@Fn)。通过将升麻提取物升麻素(Cimifugin，Ci)负载于铁蛋白中，赋予其额外的抗炎和组织保护功能，从而实现更精准、有效的治疗效果。Ci@Fn经耳后圆窗膜(RWM)注射后，随着外淋巴和内淋巴液的流动被输送到基底膜，最终靶向内耳毛细胞(HCs)。Ci@Fn进入毛细胞后，被溶酶体摄取并降解，释放出升麻素(Ci)，从而发挥对毛细胞的保护作用。
Absstract of: CN120078905A
本发明涉及IGF1‑BP偶联脂质纳米颗粒及其制备方法与应用，属于生物医药技术领域。为解决现有子痫前期预防及治疗中仍缺少针对子宫内膜的纳米载体及相应的靶向药物的问题，本发明提供了IGF1‑BP偶联脂质纳米颗粒的制备方法，分别配制有机相溶液和水相溶液，以有机相溶液和水相溶液组装脂质纳米颗粒，再通过EDC/NHS技术将IGF1‑BP通过偶联反应连接到脂质纳米颗粒表面，得到IGF1‑BP偶联脂质纳米颗粒。本发明提供的IGF1‑BP偶联脂质纳米颗粒将降低子宫内膜APOD表达的吗啉代寡核苷酸靶向递送到子宫内膜组织，不仅能够在孕期缓解子痫前期的症状，还能够对子痫前期高风险的产妇在孕前期做到预防性治疗。
Absstract of: CN118079027A
The invention relates to the field of nano-drugs, in particular to a bionic nano-system with multiple targeting characteristics and co-drug loading and application of the bionic nano-system in glioma collaborative treatment. The invention constructs a nano-drug delivery system Ang2-Pmsc-NPs with central targeting and co-drug loading, and the nano-drug delivery system Ang2-Pmsc-NPs has a good cross-BBB transport characteristic and a good permeability characteristic of tumor tissues. According to the present invention, with the application of the siRNA treatment gene and the PROTAC molecule, the GSCs can be killed, the NAD < + > energy metabolism pathway of the tumor can be inhibited, the multi-target anti-glioma effect can be achieved, and the new idea and the experimental basis can be provided for the nano-drug treatment of the glioma.
Absstract of: CN120078734A
本发明提供了一种用于核酸药物递送的脂质纳米颗粒组合物及其制备方法和应用。本发明提供的脂质纳米颗粒组合物包含类固醇‑阳离子脂质化合物、中性磷脂、和聚乙二醇脂质三种脂质成分。混合制备的组合物具有较佳的稳定性和转染效率。利用将脂质纳米颗粒用于递送核酸，例如mRNA，可以高效稳定的将核酸药物递送至靶细胞或器官，在实验动物体内可引起较高的特异性抗体应答，且化合物具有更好的安全性。
Absstract of: CN120078736A
本发明属于医药技术领域，公开了一种负载神经生长因子的仿生普鲁士蓝纳米制剂，为壳核结构，其内核为包覆有聚多巴胺涂层的普鲁士蓝纳米颗粒，在聚多巴胺涂层表面负载有神经生长因子；其外壳为仿生杂化膜。利用仿生杂化膜延长半衰期的特点，实现药物在病变部位的富集和缓慢释放；利用神经生长因子促骨生成和普鲁士蓝抗氧化两种不同机理的抗骨质疏松效应，辅助以纳米载体和仿生系统，实现骨质疏松症防治效果的最大化。还公开了其制备方法和在制备预防和/或治疗骨质疏松症药物中的应用。解决了骨质疏松症中成骨能力受损的根本问题，实现骨质疏松症部位的药物高度富集，为开发新型防治骨质疏松症的药剂及相关预防和治疗提供新理论支持。
Absstract of: CN120078743A
本发明提供了一种仿生小胶质细胞膜包覆的ZnS@BSA纳米颗粒及其制备方法和应用，属于生物纳米材料技术领域。本发明采用自组装方法，通过将醋酸锌和硫氢化钠与牛血清白蛋白(BSA)混合，合成了牛血清白蛋白的硫化锌纳米颗粒(ZnS@BSA)。由于BSA对金属离子具有亲和力以及延长半衰期的特性，可被广泛应用于纳米医学中。本发明利用挤压法制备了仿生小胶质细胞膜包覆的ZnS@BSA纳米颗粒(ZnS@BSA@MM)，ZnS@BSA@MM增强了牛血清白蛋白的硫化锌纳米颗粒在损伤部位的积累，并减少了血液循环中硫化氢的损失，促进了功能性神经元再生，抑制了神经瘢痕形成，并改善了SCI小鼠的运动功能恢复。
Absstract of: CN120078737A
本发明提供了一种具有T细胞激活能力的聚合物脂质杂化纳米颗粒，其特征在于，包括阳离子聚合物，辅助脂质，胆固醇和聚乙二醇衍生脂质，所述阳离子聚合物包括由聚乙烯亚胺和对甲苯磺酰基精氨酸制备得到的共聚物。本发明提供的聚合物脂质杂化纳米颗粒具有T细胞激活和转染的双重能力，能够实现一步激活和转染原代T细胞，大大缩短了制备周期，减少了制备的复杂性。此外，通过所述聚合物脂质杂化纳米颗粒RT LNP递送CAR mRNA产生的CAR‑T细胞在体外具有优异的细胞杀伤能力，并能够特异性分泌杀伤性细胞因子，实现对与靶细胞的特异性高效性杀伤，验证了本发明中开发的聚合物脂质杂化纳米颗粒是一个快速生产mRNA CAR T细胞产品的有前途的平台。
Absstract of: CN120082547A
本公开提供一种用于自复制mRNA的加帽类似物及其应用，所述用于自复制mRNA的加帽类似物能够提高自复制mRNA的稳定性和/或自复制mRNA的翻译效率。
Absstract of: CN120078739A
本发明涉及一种序贯靶向纳米药物及其制备方法和在心肌缺血再灌注损伤中的应用，属于纳米药物技术领域。本发明的序贯靶向纳米药物包括：通道黑色素纳米胶囊及封装在通道黑色素纳米胶囊上的环孢霉素A；通道黑色素纳米胶囊是以聚合物微球为模板，多巴胺为原料，在碱性条件下制备得到的线粒体靶向载体。该纳米药物具有超高载药率，可控释放和超强的抗氧化活性，良好的生活相容性，可以实现对从心梗组织到心肌细胞线粒体的序贯靶向，有效保护线粒体形态和功能；能显著较少心肌细胞线粒体DNA释放，抑制cGAS‑STING信号通路激活，降低心肌组织的炎症因子水平；能显著抑制caspase3凋亡信号通路激活，减少心肌细胞凋亡。
Absstract of: CN120078741A
本发明属于动物免疫增强剂技术领域，具体涉及一种具有肝靶向性的断奶仔猪免疫调节纳米颗粒及其制备方法，包括以下步骤：S1、向去离子水中加入半乳甘露聚糖，搅拌溶解后加入丁基甘油酯，调整pH在保护气下反应，反应结束后透析纯化后冻干得到丁基甘油酯修饰的半乳甘露聚糖；S2、将S1制备的丁基甘油酯修饰的半乳甘露聚糖溶解在缓冲液中，搅拌至溶解后向其中滴加水飞蓟宾乙醇溶液，超声反应得到水飞蓟宾‑半乳甘露聚糖自组装纳米颗粒；S3、向水飞蓟宾‑半乳甘露聚糖自组装纳米颗粒中加入交联剂，交联反应后透析纯化、冷冻干燥制得免疫调节纳米颗粒。本发明以水飞蓟宾为免疫调节剂，基于半乳甘露聚糖与断奶仔猪肝脏枯否细胞及树突细胞表面甘露糖受体的天然识别特性，并利用丁基甘油酯疏水特性增强半乳甘露聚糖对水飞蓟宾的纳米封装效率及其稳定性，构建一种具有断奶仔猪肝靶向性的新型免疫调节剂。
Absstract of: CN120081891A
本发明提供了一种具有式(I)所示结构的可电离阳离子脂质化合物，其可用于制备用于递送治疗剂和/或预防剂的脂质纳米颗粒(LNP)。利用本发明的可电离阳离子脂质化合物制备的LNP具有较佳的稳定性和转染效率，可以高效地、稳定地将生物活性物质(包括核酸，例如mRNA)递送至靶细胞或器官，从而在体内引起高特异性抗体应答。#imgabs0#
Absstract of: CN120081947A
一种多肽复合物、蛋白、核酸、组合物及其用途。采用细胞特异性高表达和长滞留(ePR)策略，以使肝星状细胞中的特异性mRNA过表达成治疗蛋白，并促使治疗蛋白长期锚定在纤维化的基质微环境中。确定了含有羧基的一代、二代视黄醇衍生物，能够在类脂质纳米粒(LNP)中部分替代胆固醇，通过静脉注射，富集在纤维化区域，使纤维化肝脏中mRNA表达提升约10倍。此外，通过将胶原蛋白结合结构域(CBD)的基因序列与治疗蛋白的C末端偶联，对治疗性mRNA进行了工程设计。在筛选中，发现胎盘生长因子(PLGF)的肽序列显示出最强的胶原亲和力，能够延长过表达治疗蛋白的肝脏滞留时间，并将全身副作用降至最低。
Nº publicación: CN120092082A 03/06/2025
Applicant:
可靠控股有限公司莫提格尼克斯新加坡私人有限公司
Absstract of: AU2023343598A1
Compounds, compositions, uses, and methods for reducing cell viability of a cancer cell, or for preventing or treating cancer, are provided herein. In certain examples, methods for reducing cell viability of a cancer cell and/or for preventing or treating cancer in a subject in need thereof are provided which may include a step of treatment with a GDP-bound form of Rab1a (Rab1a
BOPI
Electronic site
